Ophthalmology, Macular Degeneration Clinical Trial
Official title:
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe: A Follow-up Physician Survey
NCT number | NCT04067583 |
Other study ID # | 20285 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 8, 2019 |
Est. completion date | April 23, 2020 |
Verified date | April 2021 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire. The questionnaire will gather information related to physician characteristics and experience with Aflibercept, as well as assess physicians' knowledge and understanding of storage and preparation, proper injection technique, and the risks associated with Aflibercept injection into the eye (intravitreal injection). Analysis will be done using descriptive statistics.
Status | Completed |
Enrollment | 454 |
Est. completion date | April 23, 2020 |
Est. primary completion date | April 15, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Has signed informed consent - Is a licensed and practicing ophthalmologist - Has prescribed and/or administered aflibercept to at least one patient in the past 6 months Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
Germany | Many locations | Multiple Locations |
Lead Sponsor | Collaborator |
---|---|
Bayer |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of physicians responding correctly to each individual knowledge question | Up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01447043 -
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
|
N/A |